HER2和尿路癌:目前的理解和未来的方向
Daniele Raggi1, Emanuele Crupi2,3, Filippo Pederzoli4
1Genitourinary Oncology; The Royal Marsden Hospital NHS Foundation Trust, London, UK. daniele.raggi83@gmail.com.
Nature reviews. Urology
|August 16, 2025
概括
人类表皮生长因子受体2 (HER2) 是尿路细胞癌的关键生物标志物,特别是HER2-低瘤. 准确的HER2评估对于指导针对性疗法至关重要,例如抗体-药物合物 (ADC).
科学领域:
- 在瘤学瘤学.
- 分子诊断学 分子诊断学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 人体表皮生长因子受体2 (HER2) 是各种癌症的关键生物标志物,影响治疗和预后.
- 在尿路癌中,包括HER2低的病例,HER2阳性可以达到68%,过度表达与晚期疾病和不良结果有关.
研究的目的:
- 突出精确的HER2评估在尿路癌中的重要性,以确定符合HER2向治疗的患者.
- 讨论 HER2 低瘤作为可操作子组的潜力以及 HER2 阳性的不断变化的定义.
主要方法:
- 审查目前对HER2表达,基因组变化和尿癌异质性的理解.
- 分析不同的HER2向疗法的机制和疗效,包括铁氨酸激酶抑制剂,单克隆抗体和抗体-药物联结物 (ADC).
主要成果:
- 低HER2瘤代表了尿路癌中一个独特的和潜在的可采取行动的子组.
- 抗体-药物联合体 (ADC) 即使在低HER2表达水平下也表现出有效性,提供了新的治疗途径.
- 特拉斯图祖马布德鲁克斯坦已获得FDA批准用于不可切除或转移的HER2+固体瘤,包括尿路细胞癌.
结论:
- 对HER2状态的准确和一致的评估对于优化尿癌的治疗选择至关重要.
- 针对HER2的疗法,特别是ADC,为表达HER2的泌尿器癌患者提供了有前途的结果.
- 研究与其他生物标志物的相互作用可能会导致改善患者选择和新的组合策略.
更多相关视频
11:02Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
21.4K
09:16Ex Vivo Organoid Model of Adenovirus-Cre Mediated Gene Deletions in Mouse Urothelial Cells
Published on: May 5, 2022
2.7K
相关概念视频
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
02:38Mitogens and the Cell Cycle
6.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.7K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
01:26Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
40
Renal calculi, commonly termed kidney stones, are crystalline solid masses that form in the kidneys but can occur at any point within the urinary system, encompassing the kidneys, ureters, bladder, and urethra.The pathophysiology of renal stones involves several key factors: supersaturation of the urine with stone-forming constituents, changes in urine pH, a decrease in urine volume, and the presence of substances that promote or inhibit stone formation.Supersaturation of Urine: This is the...
40